P1672 Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of beta-lactam agents against a challenge set of Gram-negative pathogens

Background: Enterobacteriaceae can express a diverse array of β-lactam antimicrobial resistance mechanisms, including β-lactamase enzymes, which can compromise therapy. SPR741 is a novel polymyxin B derivative with minimal intrinsic antibacterial activity and reduced nonclinical nephrotoxicity. This study assessed in vitro activity of a series of β-lactam agents tested in combination with SPR741 against a challenge set of pathogens.